Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Monica Barbolini

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Cancer Treatment Reviews|November 14, 2016
The evolving role of microsatellite instability in colorectal cancer: A reviewFabio Gelsomino, Monica Barbolini, Andrea Spallanzani, et al.
Breast (Edinburgh, Scotland)|June 9, 2020
Henoch-schönlein Purpura (HSP) in a patient on AbemaciclibClaudia Omarini, Eleonora Molinaro, Monica Barbolini, et al.
International Journal of Molecular Sciences|July 9, 2022
Role of Intrinsic Subtype Analysis with PAM50 in Hormone Receptors Positive HER2 Negative Metastatic Breast Cancer: A Systematic ReviewFabio Canino, Federico Piacentini, Claudia Omarini, et al.
Immunotherapy|November 30, 2020
Pembrolizumab rechallenge in squamous non-small-cell lung cancer and HIV-positivity: a case reportGiorgia Guaitoli, Fausto Barbieri, Monica Barbolini, et al.
BMC Cancer|May 15, 2020
Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: to prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trialsClaudia Omarini, Federico Piacentini, Isabella Sperduti, et al.
Translational Oncology|June 3, 2020
Modulation of Mutational Landscape in HER2-Positive Breast Cancer after Neoadjuvant ChemotherapyClaudia Omarini, Stefania Bettelli, Samantha Manfredini, et al.
BMC Cancer|June 7, 2022
T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysisClaudia Omarini, Federico Piacentini, Isabella Sperduti, et al.
Biomedicines|January 21, 2023
Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical ChallengesKrisida Cerma, Federico Piacentini, Luca Moscetti, et al.
Clinical Breast Cancer|September 29, 2023
Thromboembolism and Adjuvant Endocrine Therapy (AET) in Hormone Receptor-Positive Early Breast Cancer (EBC): Did Treatment Evolution Change Incidence of the Adverse Event? A Meta-AnalysisRaffaella D'Onofrio, Isabella Sperduti, Federico Piacentini, et al.
Cancers|October 13, 2021
Circulating and Intracellular miRNAs as Prognostic and Predictive Factors in HER2-Positive Early Breast Cancer Treated with Neoadjuvant Chemotherapy: A Review of the LiteratureChrystel Isca, Federico Piacentini, Ilenia Mastrolia, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Cancer Treatment Reviews|November 14, 2016
The evolving role of microsatellite instability in colorectal cancer: A reviewFabio Gelsomino, Monica Barbolini, Andrea Spallanzani, et al.
Breast (Edinburgh, Scotland)|June 9, 2020
Henoch-schönlein Purpura (HSP) in a patient on AbemaciclibClaudia Omarini, Eleonora Molinaro, Monica Barbolini, et al.
International Journal of Molecular Sciences|July 9, 2022
Role of Intrinsic Subtype Analysis with PAM50 in Hormone Receptors Positive HER2 Negative Metastatic Breast Cancer: A Systematic ReviewFabio Canino, Federico Piacentini, Claudia Omarini, et al.
Immunotherapy|November 30, 2020
Pembrolizumab rechallenge in squamous non-small-cell lung cancer and HIV-positivity: a case reportGiorgia Guaitoli, Fausto Barbieri, Monica Barbolini, et al.
BMC Cancer|May 15, 2020
Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: to prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trialsClaudia Omarini, Federico Piacentini, Isabella Sperduti, et al.
Translational Oncology|June 3, 2020
Modulation of Mutational Landscape in HER2-Positive Breast Cancer after Neoadjuvant ChemotherapyClaudia Omarini, Stefania Bettelli, Samantha Manfredini, et al.
BMC Cancer|June 7, 2022
T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysisClaudia Omarini, Federico Piacentini, Isabella Sperduti, et al.
Biomedicines|January 21, 2023
Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical ChallengesKrisida Cerma, Federico Piacentini, Luca Moscetti, et al.
Clinical Breast Cancer|September 29, 2023
Thromboembolism and Adjuvant Endocrine Therapy (AET) in Hormone Receptor-Positive Early Breast Cancer (EBC): Did Treatment Evolution Change Incidence of the Adverse Event? A Meta-AnalysisRaffaella D'Onofrio, Isabella Sperduti, Federico Piacentini, et al.
Cancers|October 13, 2021
Circulating and Intracellular miRNAs as Prognostic and Predictive Factors in HER2-Positive Early Breast Cancer Treated with Neoadjuvant Chemotherapy: A Review of the LiteratureChrystel Isca, Federico Piacentini, Ilenia Mastrolia, et al.
Pageof 2